President Donald Trump unveiled his plan for a vaccine distribution despite the Centers for Disease Control and Prevention saying it may not be widely available until the middle of 2021. (Sept. 16)

AP Domestic

WASHINGTON – The Food and Drug Administration laid out updated safety standards Tuesday for makers of COVID-19 vaccines after the White House blocked their formal release, the latest political tug-of-war between the Trump administration and the government’s public health scientists.

In briefing documents posted on its website, the FDA said vaccine makers should follow trial participants for at least two months to rule out safety issues before seeking emergency approval. That requirement would almost certainly preclude the introduction of a vaccine before Nov. 3.

President Donald Trump has repeatedly insisted a vaccine could be authorized before Election Day, even though top government scientists working on the effort have said that timeline is very unlikely. On Monday, Trump said vaccines are coming “momentarily,” in a video recorded after he returned to the White House.

From COVID-19 to voting: Trump is nation’s single largest spreader of disinformation, studies say

Former FDA officials have warned that public perception that a vaccine was being rushed out for political reasons could derail efforts to vaccinate millions of Americans.

A senior administration official confirmed to the AP on Monday that the White House had blocked FDA’s plans to formally publish the safety guidelines based on the 2-month data requirement, arguing there was “no clinical or medical reason” for it.

But the FDA tucked the information into a memo posted ahead of an Oct. 22 meeting of its outside vaccine advisory panel. The group of non-governmental experts is scheduled to discuss general standards for coronavirus vaccines, part of FDA’s effort to publicize its process and rationale for vaccine reviews. While information prepared for such panels does not carry the weight of a formal FDA guidance document, the release of the information makes clear the FDA plans to impose the safety standards for any vaccine seeking an expedited path to market.

To meet the FDA’s threshold, companies would need to submit two months of follow-up from half of their trial participants after they receive their last vaccine dose to show there are no major side effects or health problems. Because vaccines are normally given to otherwise healthy people the FDA requires strict evidence of their safety.

The requirements are aimed at companies seeking rapid approval through the FDA’s emergency authorization pathway. That accelerated process, reserved for health emergencies, allows medical products onto the market based on a lower bar than traditional FDA approval.

Vaccines coming ‘momentarily’: Trump says COVID-19 vaccines are coming soon. Scientists say they’re not.

Should Trump have left the hospital?: Donald Trump, infected with COVID-19, has returned to the White House. Doctors offer varying opinions on whether it was a good idea.

Initial doses of vaccines for emergency use